Metabolic steatotic liver disease

1. Dapagliflozin decreases metabolic steatotic liver disease in mice.

   “Intervention resulted in a reduction in adiposity without compromising muscle mass, preservation of mitochondrial integrity, improvement in mitochondrial bioenergetics, and attenuation of steatosis and hepatic cellular stress.”

   Animalsin high-fat diet and fructose-fed micesaline solution via orogastric gavageliver10 mg/kg6 weeks

   Dapagliflozin attenuates hepatic steatosis and induces a fasting-mimicking metabolic state in C57BL/6 mice

   Naunyn-Schmiedeberg's archives of pharmacology·23 Jul 2026

More on Dapagliflozin